In melanoma, BRAF and NRAS mutations promote cell proliferation by activating the MAPK/ERK pathway, while CDKN2A mutations further enhance tumor cell proliferation by removing inhibition of the cell cycle. Here, CDKN2A is linked to neoplasm.